Charles River Laboratories International, Inc. (NYSE:CRL) Director C Richard Reese sold 10,227 shares of Charles River Laboratories International stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $102.40, for a total transaction of $1,047,244.80. Following the transaction, the director now owns 51,444 shares in the company, valued at approximately $5,267,865.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Charles River Laboratories International, Inc. (NYSE CRL) traded up $0.70 on Friday, hitting $103.84. 174,576 shares of the company were exchanged, compared to its average volume of 448,599. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. Charles River Laboratories International, Inc. has a 52 week low of $73.13 and a 52 week high of $119.05. The stock has a market cap of $4,920.00, a PE ratio of 20.26, a price-to-earnings-growth ratio of 1.64 and a beta of 0.89.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.22 by $0.08. The business had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.18 EPS. equities research analysts anticipate that Charles River Laboratories International, Inc. will post 5.13 EPS for the current year.

CRL has been the topic of several analyst reports. Robert W. Baird reiterated a “buy” rating and set a $114.00 price target on shares of Charles River Laboratories International in a research note on Friday, September 1st. Bank of America dropped their price target on shares of Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research note on Tuesday, October 24th. Royal Bank Of Canada began coverage on shares of Charles River Laboratories International in a research note on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 target price on the stock. Finally, Credit Suisse Group restated a “neutral” rating and set a $112.00 target price (up previously from $95.00) on shares of Charles River Laboratories International in a research note on Monday, October 16th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $106.63.

Hedge funds have recently made changes to their positions in the business. YorkBridge Wealth Partners LLC lifted its stake in Charles River Laboratories International by 445.5% in the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock worth $118,000 after purchasing an additional 891 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its stake in Charles River Laboratories International by 69.0% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after purchasing an additional 548 shares in the last quarter. Advisor Group Inc. lifted its stake in Charles River Laboratories International by 159.4% in the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after purchasing an additional 945 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Charles River Laboratories International by 12.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after purchasing an additional 202 shares in the last quarter. Finally, Riverhead Capital Management LLC lifted its stake in Charles River Laboratories International by 14.7% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after purchasing an additional 247 shares in the last quarter. Institutional investors and hedge funds own 96.27% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Charles River Laboratories International, Inc. (CRL) Director C Richard Reese Sells 10,227 Shares” was published by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.watchlistnews.com/charles-river-laboratories-international-inc-crl-director-c-richard-reese-sells-10227-shares/1753992.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.